Home show
 

Keywords :   


Tag: show

Egyptian Public and Military Institutions Show Interest in HIMOINSA's Generator Sets

2016-06-08 17:18:00| Power Technology

The 'OTRAC MANEUVER D4YS' event, that took place in the city of Sharm el-Sheikh, on the Red Sea coast, attracted more than 200 visitors, including representatives of other Egyptian bodies such as the National Organisation for Potable Water or the Nat

Tags: show public interest sets

 

ORNL, XALT show nanoscale alumina coating on layered oxide cathode materials substantially improves Li-ion battery performance

2016-06-06 17:56:32| Green Car Congress

Tags: show performance materials battery

 
 

ORNL, XALT show nanoscale alumina coating on layered oxide cathode materials substantially improves Li-ion battery performance

2016-06-06 17:56:32| Green Car Congress

Tags: show performance materials battery

 

Updated Findings from KEYNOTE-012 for KEYTRUDA (pembrolizumab) Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Previously Treated Recurrent or Metastatic Head and Neck Cancer

2016-06-06 14:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Response Rates from KEYNOTE-055 Show Nearly One in Five Patients Responding with KEYTRUDA; Results Confirm Findings from KEYNOTE-012 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data with KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy from two studies (KEYNOTE-012 and KEYNOTE-055) in heavily pre-treated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Data are being presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: or with show updated

 

New Data from Phase 2 Study Evaluating KEYTRUDA (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers

2016-06-05 19:43:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced updated findings from a study evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in patients with advanced cancers characterized as deficient for DNA mismatch repair (MMR). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of show data range

 

Sites : [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] next »